Aardvark Therapeutics, Inc. AARD
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 141.28% | 136.60% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.00% | 140.38% | -- | -- | -- |
| Operating Income | -81.00% | -140.38% | -- | -- | -- |
| Income Before Tax | -90.76% | -152.05% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.76% | -152.05% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.76% | -152.05% | -- | -- | -- |
| EBIT | -81.00% | -140.38% | -- | -- | -- |
| EBITDA | -81.02% | -140.38% | -- | -- | -- |
| EPS Basic | 29.93% | 39.28% | -- | -- | -- |
| Normalized Basic EPS | 29.38% | 38.96% | -- | -- | -- |
| EPS Diluted | 29.93% | 39.28% | -- | -- | -- |
| Normalized Diluted EPS | 29.38% | 38.96% | -- | -- | -- |
| Average Basic Shares Outstanding | 103.00% | 245.07% | -- | -- | -- |
| Average Diluted Shares Outstanding | 103.00% | 245.07% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |